Overview
Captain T Cell, a biotech company specializing in TCR-T cell therapies for solid tumors, secured €20 million in funding led by Springboard Health Angels and Pluton Asset Holding AG. This financing will advance its CTC127 program into phase I trials, addressing the urgent need for effective cancer treatments.
Products
Loading...
Recent Deals
Investors: Springboard Health Angels, Pluton Asset Holding AG
Captain T Cell, a biotech company specializing in TCR-T cell therapies for solid tumors, secured €20 million in funding led by Springboard Health Angels and Pluton Asset Holding AG. This financing will advance its CTC127 program into phase I trials, addressing the urgent need for effective cancer treatments.